News
PRNAF
0.139
-30.40%
-0.061
Alterity Therapeutics Reports 2026 Annual General Meeting Results
TipRanks · 2d ago
Alterity Reports FDA Alignment on ATH434 Phase 3 Design
TipRanks · 2d ago
Alterity Therapeutics Secures FDA Alignment and New Patent as ATH434 Advances Toward Phase 3
TipRanks · 10/30 01:13
Alterity Therapeutics Plans New ASX Option Issue to Bolster Capital Structure
TipRanks · 10/23 05:39
Alterity Therapeutics Issues New Unlisted Employee Options
TipRanks · 10/22 23:48
Alterity Therapeutics Grants New Unlisted Employee Options
TipRanks · 10/22 23:48
Alterity Therapeutics Sets Hybrid 2026 AGM, Urges Early Proxy Voting
TipRanks · 10/21 05:18
Alterity Therapeutics Updates CEO Remuneration as Neurodegeneration Programs Advance
TipRanks · 10/21 05:17
Alterity Therapeutics to Present at Canaccord Genuity Drug and Device Conference
TipRanks · 10/09 04:07
Alterity’s ATH434 slowed multiple system atrophy decline 52% in new data
TipRanks · 10/05 13:20
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
Barchart · 10/05 06:05
Alterity’s ATH434 Phase 2 Data Strengthen Case for MSA Phase 3 Trial
TipRanks · 10/04 23:22
Alterity Flags Development Risks Around Lead Neurodegeneration Drug ATH434
TipRanks · 09/23 00:09
Parties in the Matter of Athene Holding Ltd v Imran Siddiqui Announce Settlement
Barchart · 09/18 07:30
Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference
TipRanks · 09/17 23:48
Alterity Therapeutics Seeks Quotation for New ASX Shares
TipRanks · 09/16 02:43
Alterity Therapeutics management to meet virtually with Lake Street
TipRanks · 09/15 13:45
Alterity Therapeutics initiated with a Buy at Lake Street
TipRanks · 09/15 11:50
Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal
TipRanks · 09/08 02:07
Alterity Therapeutics Seeks ASX Quotation for 8.4 Million New Shares
TipRanks · 09/08 01:52
More
Webull provides a variety of real-time PRNAF stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.